N-羟基-4-甲基-1-哌啶甲脒 | 721450-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-羟基-4-甲基-1-哌啶甲脒
• 英文名称: N-Hydroxy-4-methylpiperidine-1-carboxamidine
• 英文别名: N'-hydroxy-4-methylpiperidine-1-carboximidamide
• CAS: 721450-19-7
• 化学式: C₇H₁₅N₃O
• 分子量: 157.216
• InChiKey: GGHFDZGENJOGQE-UHFFFAOYSA-N

物化性质

• 沸点：
  244.5±23.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-羟基-4-甲基-1-哌啶甲脒 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 18.0h， 生成 (S)-1-methyl-N-(1-(3-(4-methylpiperidin-1-yl)-1,2,4-oxadiazol-5-yl)ethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
  参考文献：
  名称：

  [EN] KCNT1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS DE KCNT1 ET MÉTHODES D'UTILISATION

  摘要：

  Disclosed herein are compounds and compositions useful for preventing and/or treating a neurological disorder, a disorder associated with excessive neuronal excitability, or a disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disorder, a disorder associated with excessive neuronal excitability, or disorder associated with a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

  公开号：

  WO2022231872A1
• 作为产物：
  描述：

  4-甲基哌啶-1-腈 在 盐酸羟胺 、 三乙胺 作用下， 以 乙醇 为溶剂， 以74 %的产率得到N-羟基-4-甲基-1-哌啶甲脒
  参考文献：
  名称：

  [EN] KCNT1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS DE KCNT1 ET MÉTHODES D'UTILISATION

  摘要：

  Disclosed herein are compounds and compositions useful for preventing and/or treating a neurological disorder, a disorder associated with excessive neuronal excitability, or a disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disorder, a disorder associated with excessive neuronal excitability, or disorder associated with a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

  公开号：

  WO2022231872A1

文献信息

• 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cytovia, Inc.

  公开号：US20040127521A1

  公开（公告）日：2004-07-01

  Disclosed are 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: 1 wherein Ar 1 , R 2 , A, B and D are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  揭示了3,5-二取代-[1,2,4]-噁二唑及其类似物，由式I所表示：其中Ar1、R2、A、B和D在此处定义。本发明涉及发现具有式I的化合物是半胱氨酸蛋白酶激活剂和凋亡诱导剂。因此，本发明的半胱氨酸蛋白酶激活剂和凋亡诱导剂可用于诱导在各种临床病况中发生细胞死亡的情况，其中出现了异常细胞的不受控制的生长和扩散。
• 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use of thereof
  申请人：Cai Xiong Sui

  公开号：US20070112003A1

  公开（公告）日：2007-05-17

  Disclosed are 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar 1 , R 2 , A, B and D are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及3,5-二取代-[1,2,4]-噁二唑及其类似物，由式I表示：其中Ar1、R2、A、B和D在此定义。本发明涉及发现具有式I的化合物是caspase的激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导在不受控制的异常细胞生长和扩散的各种临床状况中的细胞死亡。
• COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
  申请人：Alper Phillip B.

  公开号：US20120196844A1

  公开（公告）日：2012-08-02

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.

  本发明提供了化合物、包含这些化合物的药物组成物以及使用这些化合物治疗或预防与GPR119活性相关的疾病或疾病的方法。
• 3,5-DISUBSTITUTED- 1,2,4 -OXADIAZOLES AND ANALOGS AS AC TIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
  申请人：Cytovia, Inc.

  公开号：EP1581213A1

  公开（公告）日：2005-10-05
• EP1581213A4
  申请人：——

  公开号：EP1581213A4

  公开（公告）日：2008-11-19